Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Pfizer to seek COVID booster for healthy 5- to 11-year-olds

Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds

Via AP news wire
Thursday 14 April 2022 07:34 EDT
Virus Outbreak-Kid Booster
Virus Outbreak-Kid Booster (Copyright 2021 The Associated Press. All rights reserved.)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Pfizer said Thursday it wants to expand its COVID-19 booster shots to healthy elementary-age kids.

U.S. health authorities already urge everyone 12 and older to get one booster dose for the best protection against the newest variants -- and recently gave the option of a second booster to those 50 and older.

Now Pfizer says new data shows healthy 5- to 11-year-olds could benefit from another kid-sized shot.

In a small study, 140 youngsters who’d already gotten two shots were given a booster six months later, and researchers found the extra shot generally revved up their immune response. But a closer look at 30 of the children found a 36-fold increase in virus-fighting antibodies, levels high enough to fight the super-contagious omicron variant, Pfizer and its partner BioNTech said in a press release.

The data has not been published or vetted by independent experts.

Pfizer tested the kid booster while omicron was surging this winter. While COVID-19 cases now are at much lower levels in the U.S., in recent weeks an even more contagious version of omicron, called BA.2, has become the dominant type locally and around the world.

In the coming days, the companies plan to ask the U.S. Food and Drug Administration to authorize a booster for healthy 5- to 11-year-olds. They also plan to share the data with European and other regulators.

Vaccinations are generally less effective against the omicron variant than earlier versions of the coronavirus -- but they do still offer strong protection against severe disease. While COVID-19 is a bigger threat to adults, youngsters can get seriously ill. But regulators will have to decide if healthy elementary-age kids really need a booster, and if so, when.

The Pfizer shots are the only vaccine available to U.S. children. Those ages 5 to 11 receive one-third of the dose given to everyone 12 and older. Just over a quarter in the younger age group have gotten two doses since vaccination opened to them in November, shortly before omicron struck.

The U.S. hasn’t yet allowed vaccinations for children under 5. But certain 5- to 11-year-olds -- those with severely weakened immune systems -- already are supposed to get three doses, to give that high-risk group a better chance of responding.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in